Corpus ID: 7885913

Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.

@article{Boissier1997BisphosphonatesIP,
  title={Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.},
  author={S. Boissier and S. Magnetto and L. Frappart and B. Cuzin and F. Ebetino and P. Delmas and P. Cl{\'e}zardin},
  journal={Cancer research},
  year={1997},
  volume={57 18},
  pages={
          3890-4
        }
}
The molecular mechanisms by which tumor cells induce osteolytic metastases are likely to involve tumor cell adhesion to bone as well as the release of soluble mediators from tumor cells that stimulate osteoclast-mediated bone resorption. Bisphosphonates (BPs) are powerful inhibitors of the osteoclast activity and are, therefore, used in the treatment of cancer-associated osteolytic metastases. Here, we investigated the effect of BPs on breast and prostate carcinoma cell adhesion to… Expand
Bisphosphonates in cancer therapy
  • J. Green
  • Medicine
  • Current opinion in oncology
  • 2002
Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Extracellular matrix synthesized by clonal osteogenic cells is osteoinductive in vivo and in vitro: Role of transforming growth factor‐beta1 in osteoblast cell‐matrix interaction
  • M. Kirk, A. Kahn
  • Biology, Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1995
Mechanisms of preferential metastasis of breast cancer to bone - (Review).
  • T. Yoneda
  • Biology, Medicine
  • International journal of oncology
  • 1996
Bisphosphonates: Mechanisms of Action
...
1
2
...